Transaminase mutant and applications of transaminase mutant in Sitagliptin synthesis
Patent Information
- Authority / Receiving Office
- CN Β· China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SHANXI WEIQIDA PHARMA IND
- Publication Date
- 2020-12-18
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the technical field of genetic engineering and enzyme catalysis, and in particular relates to a transaminase mutant and its application in the synthesis of sitagliptin. Background technique
[0002] Sitagliptin, also known as sitagliptin, its full name is 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5 ,6,7,8-tetrahydro-3-trifluoromethyl-1,2,4-triazolo[4,3-a]pyrazine is the first dipeptide developed by Merck DPP-4 inhibitors, and their phosphorylated hydrates are currently type II diabetes drugs that occupy a huge market share.
[0003] In the synthetic route of sitagliptin, the introduction of chiral (R)-amino group is one of the key steps. At present, methods including chiral source introduction, selective reduction, chiral induction and kinetic resolution have been developed. Among them, (2Z)-4-oxo-4-[3-(trifluoromethyl)-5,6- Dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7-(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2- Keton...